Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
4-22 January 2021

ACCESS CHINA Forum @JPM Week 2021

26-28 January 2021

Edison’s Open House – Global Healthcare 2021

6-11 January 2021

LifeSci Advisors’ 10th Annual LifeSci Advisors Corporate Access Event 2021

11-14 January 2021

H.C. Wainwright Bioconnect Conference

4 January 2021

ORYZON to present a corporate update and to hold multiple virtual corporate activities in January-2021

17 December 2020

ORYZON Launches Pioneering Schizophrenia Precision Medicine Study In Collaboration With Columbia Psychiatry

7 December 2020

ORYZON presents new robust Phase II iadademstat efficacy data in AML at ASH-2020

20 November 2020

Borderline Personality Disorder Day organized by the Spanish BPD Association, AMAI-TLP

17-19 November 2020

Jefferies 2020 Virtual London Healthcare Conference

5-8 December 2020

62nd American Society of Hematology Conference, ASH 2020

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 25
  • Page 26
  • Page 27
  • Page 28
  • Current page 29
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel